|
|
|
|
Tuesday, June 16, 2020
Cocrystal Pharma Inc. (COCP)
Cocrystaling to combat viral diseases, Initiating Coverage
Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Initiation of Coverage. We are initiating coverage on Cocrystal Pharma (COCP).. In our view, Cocrystal remains under the Street’s radar with its pipeline. Its versatile technology platform enables growth in new directions. As we look forward, we believe that three ongoing preclinical programs (influenza, coronavirus, and norovirus) may provide dynamic catalysts for the near/medium term. In addition, one IND filing (influenza program), expected in Q4 2020, provides fundamental depth to future value.
The platform is foremost. Cocrystal uses a proprietary platform to identify drug candidates to treat viral diseases. The anti-viral therapy segment is expected to reach…
Click to get the full report.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.